Products found to contain undeclared medicines
|
| |
| The United States: Public Notification: Lipo Escultura contains hidden drug ingredients sibutramine and diclofenac |
| |
The Food and Drug Administration (FDA) is advising consumers not to purchase or use Lipo Escultura, a product promoted and sold for weight loss on www.lipoesculturatreatment.com by JAT Productos Naturales Corp., but may also be distributed under the following aliases: Lipo Escultura Corporation and JAT Natural Products Corp. This product is also heavily promoted on the firm's Facebook and Instagram accounts.
FDA laboratory analysis confirmed that Lipo Escultura contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons. The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.
Laboratory analysis also confirmed that Lipo Escultura contains diclofenac. Diclofenac is a non-steroidal anti-inflammatory drug (commonly referred to as NSAIDs). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.
Please refer to the following website in FDA for details:
http://www.fda.gov/Drugs/ResourcesForYou/../ucm475356.htm
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/ Thursday, December 03, 2015
Issued at HKT 14:00
|
| |
|
